305 related articles for article (PubMed ID: 22431917)
1. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism.
Wong HK; Shimizu A; Kirkpatrick ND; Garkavtsev I; Chan AW; di Tomaso E; Klagsbrun M; Jain RK
Neoplasia; 2012 Feb; 14(2):84-94. PubMed ID: 22431917
[TBL] [Abstract][Full Text] [Related]
2. The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.
Ammoun S; Schmid MC; Ristic N; Zhou L; Hilton D; Ercolano E; Carroll C; Hanemann CO
Glia; 2012 Nov; 60(11):1721-33. PubMed ID: 22821509
[TBL] [Abstract][Full Text] [Related]
3. The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells.
Bashour AM; Meng JJ; Ip W; MacCollin M; Ratner N
Mol Cell Biol; 2002 Feb; 22(4):1150-7. PubMed ID: 11809806
[TBL] [Abstract][Full Text] [Related]
4. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
[TBL] [Abstract][Full Text] [Related]
5. Generation and Use of Merlin-Deficient Human Schwann Cells for a High-Throughput Chemical Genomics Screening Assay.
Petrilli AM; Fernández-Valle C
Methods Mol Biol; 2018; 1739():161-173. PubMed ID: 29546707
[TBL] [Abstract][Full Text] [Related]
6. Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis.
Schulze KM; Hanemann CO; Müller HW; Hanenberg H
Hum Mol Genet; 2002 Jan; 11(1):69-76. PubMed ID: 11773000
[TBL] [Abstract][Full Text] [Related]
7. Calpain-dependent proteolysis of NF2 protein: involvement in schwannomas and meningiomas.
Kimura Y; Saya H; Nakao M
Neuropathology; 2000 Sep; 20(3):153-60. PubMed ID: 11132929
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein.
Lee H; Kim D; Dan HC; Wu EL; Gritsko TM; Cao C; Nicosia SV; Golemis EA; Liu W; Coppola D; Brem SS; Testa JR; Cheng JQ
Mol Cell Biol; 2007 Mar; 27(6):2103-19. PubMed ID: 17210637
[TBL] [Abstract][Full Text] [Related]
9. Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma.
Flaiz C; Ammoun S; Biebl A; Hanemann CO
Brain Pathol; 2009 Jan; 19(1):27-38. PubMed ID: 18445079
[TBL] [Abstract][Full Text] [Related]
10. Cellular prion protein (PrP
Provenzano L; Ryan Y; Hilton DA; Lyons-Rimmer J; Dave F; Maze EA; Adams CL; Rigby-Jones R; Ammoun S; Hanemann CO
Oncogene; 2017 Nov; 36(44):6132-6142. PubMed ID: 28692055
[TBL] [Abstract][Full Text] [Related]
11. Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells.
Flaiz C; Utermark T; Parkinson DB; Poetsch A; Hanemann CO
Glia; 2008 Apr; 56(5):506-15. PubMed ID: 18240308
[TBL] [Abstract][Full Text] [Related]
12. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.
Wong HK; Lahdenranta J; Kamoun WS; Chan AW; McClatchey AI; Plotkin SR; Jain RK; di Tomaso E
Cancer Res; 2010 May; 70(9):3483-93. PubMed ID: 20406973
[TBL] [Abstract][Full Text] [Related]
13. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.
Giovannini M; Bonne NX; Vitte J; Chareyre F; Tanaka K; Adams R; Fisher LM; Valeyrie-Allanore L; Wolkenstein P; Goutagny S; Kalamarides M
Neuro Oncol; 2014 Apr; 16(4):493-504. PubMed ID: 24414536
[TBL] [Abstract][Full Text] [Related]
14. Reduced RAC1 activity inhibits cell proliferation and induces apoptosis in neurofibromatosis type 2(NF2)-associated schwannoma.
Wang Y; Wang B; Li P; Zhang Q; Liu P
Neurol Res; 2017 Dec; 39(12):1086-1093. PubMed ID: 28934903
[TBL] [Abstract][Full Text] [Related]
15. Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function.
Yang C; Asthagiri AR; Iyer RR; Lu J; Xu DS; Ksendzovsky A; Brady RO; Zhuang Z; Lonser RR
Proc Natl Acad Sci U S A; 2011 Mar; 108(12):4980-5. PubMed ID: 21383154
[TBL] [Abstract][Full Text] [Related]
16. The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.
Zhou L; Lyons-Rimmer J; Ammoun S; Müller J; Lasonder E; Sharma V; Ercolano E; Hilton D; Taiwo I; Barczyk M; Hanemann CO
Oncogene; 2016 Jun; 35(26):3443-53. PubMed ID: 26549023
[TBL] [Abstract][Full Text] [Related]
17. An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.
Stepanova DS; Semenova G; Kuo YM; Andrews AJ; Ammoun S; Hanemann CO; Chernoff J
Cancer Res; 2017 Sep; 77(18):5026-5038. PubMed ID: 28729415
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis.
Petrilli A; Bott M; Fernández-Valle C
Oncotarget; 2013 Dec; 4(12):2354-65. PubMed ID: 24259290
[TBL] [Abstract][Full Text] [Related]
19. Universal absence of merlin, but not other ERM family members, in schwannomas.
Stemmer-Rachamimov AO; Xu L; Gonzalez-Agosti C; Burwick JA; Pinney D; Beauchamp R; Jacoby LB; Gusella JF; Ramesh V; Louis DN
Am J Pathol; 1997 Dec; 151(6):1649-54. PubMed ID: 9403715
[TBL] [Abstract][Full Text] [Related]
20. VprBP targets Merlin to the Roc1-Cul4A-DDB1 E3 ligase complex for degradation.
Huang J; Chen J
Oncogene; 2008 Jul; 27(29):4056-64. PubMed ID: 18332868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
